Search

Your search keyword '"Miyazaki, H."' showing total 128 results
Start Over Author "Miyazaki, H." Publisher elsevier bv
128 results on '"Miyazaki, H."'

11. Lysis of autologous tumor cells by large granular lymphocytes in patients with acute leukemia in complete remission: Correlation between lytic activity and clinical outcome

Author

Miyazaki H, Masataka Okamoto, Matsui T, Masami Hirano, Kojima H, Maruyama F, Ezaki K, Wakita M, Nomura T, Ino T, and Motohiro Tsuzuki

Subjects
Adult, Male, Cancer Research, Cellular immunity, medicine.medical_specialty, Adolescent, Lymphocyte, Gastroenterology, Myelogenous, Recurrence, Acute lymphocytic leukemia, Internal medicine, Humans, Medicine, Cytotoxic T cell, Lymphocytes, Child, Aged, Retrospective Studies, Acute leukemia, business.industry, Remission Induction, Hematology, Middle Aged, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Prognosis, medicine.disease, Leukemia, Myeloid, Acute, Leukemia, medicine.anatomical_structure, Oncology, Immunology, Female, business, K562 cells
Abstract

In order to evaluate the effect of specific immune response on prognosis in acute leukemia, we investigated the correlation between the lysis of autologous tumor cells (ATC) by lymphocytes and prognosis. Peripheral mononuclear cells (PMC) from most patients with acute leukemia in complete remission (CR) do not exhibit cytotoxic activity against fresh-frozen ATC, although they have adequate cytotoxic activity against K562 cells. When the large granular lymphocyte (LGL) fraction was used in this study, we observed lysis of ATC in 17 (43.6%) of 39 patients with acute leukemia (12 (42.9%) of the 28 patients with acute myelogenous leukemia (AML) and 5 (45.5%) of the 11 patients with acute lymphocytic leukemia (ALL)). With regard to prognosis, the lytic activity of the LGL fraction did not reflect the duration of CR. The median CR duration in AML patients was 13 months for the lysis-positive group and 11 months for the lysis-negative group. No significant correlation was also found between lytic activity of the LGL fraction and overall survival in each patient. However, the lysis-positive group tended to have a longer survival, the median overall survival being 48 months for the lysis-positive group vs 12 months for the lysis-negative group. The prolonging of overall survival in the lysis-positive group was attributed to a high rate of induction of second remissions in this group. Long-term patient survival in the two groups did not differ.

Published
1994

17. Intensive sequential post-induction therapy for adults with acute myelogenous leukemia in first remission: Long-term follow-up and results

Author

Sobue R, Maruyama F, Masataka Okamoto, Matsui T, Miyazaki H, Kazuyuki Shimizu, Kojima H, Ino T, Ezaki K, and Masami Hirano

Subjects
Adult, Male, Cancer Research, medicine.medical_specialty, Adolescent, Long term follow up, Prednisolone, medicine.medical_treatment, Myelogenous, Induction therapy, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Life Tables, Aclarubicin, Aged, Etoposide, Chemotherapy, Mercaptopurine, business.industry, Daunorubicin, Remission Induction, Cytarabine, First remission, Hematology, Middle Aged, medicine.disease, Confidence interval, Surgery, Survival Rate, Leukemia, Myeloid, Acute, Leukemia, Oncology, Toxicity, Female, Mitoxantrone, business, Follow-Up Studies
Abstract

We designed a post-induction therapy including intensive sequential therapy with non-cross-resistant drugs in an effort to prolong disease-free survival (DFS) for adults with acute myelogenous leukemia. Forty-five patients entered this study and 33 of 35 patients entering complete remission received the post-induction therapy. With a median follow-up for survivors of 3.5 years from complete remission, the actuarial 5-year DFS was 46% ± 19% (95% confidence interval). The five-year DFS for patients over 45 years of age was comparable to that for patients under 45 years of age (50% ± 26% vs 47% ± 28%). Furthermore, the actuarial 5-year DFS for patients who required two courses of induction therapy was comparable to that for patients who required only one course of induction therapy (45% ± 29% vs 50% ± 25%). The toxicity of post-induction therapy was tolerable and no patients died during complete remission.

Published
1992

21. Translocation (3;21)(q26;q22) in treatment-related acute leukemia secondary to acute promyelocytic leukemia

Author

Nomura T, Motohiro Tuzuki, Ino T, Kojima H, Miyazaki H, Sobue R, Wakita M, and Masami Hirano

Subjects
Male, Acute promyelocytic leukemia, Cancer Research, Acute leukemia, Chemotherapy, Leukemia, medicine.medical_treatment, Induction chemotherapy, Chromosomal translocation, Middle Aged, Biology, medicine.disease, Neoplasms, Multiple Primary, Leukemia, Promyelocytic, Acute, Karyotyping, Acute Disease, Genetics, medicine, Cancer research, Humans, Topoisomerase II Inhibitors, Prolymphocytic leukemia, Molecular Biology, Metaphase
Abstract

We performed cytogenetic studies in a patient with treatment-related acute leukemia (t-AL) to identify the associated chromosomal changes. Metaphase analysis revealed a t(3;21)(q26;q22) translocation. Acute promyelocytic leukemia (APL) had been diagnosed 4 years earlier and the patient had received intensive induction chemotherapy and sequential post-induction therapy that included agents that targeted DNA-topoisomerase II (topo II). This case suggests an association between previous therapy with topo II inhibitors and development of t-AL associated with a balanced aberration involving the 3q26 and 21q22 bands.

Published
1994

28. High-angle triple-axis specimen holder for three-dimensional diffraction contrast imaging in transmission electron microscopy

Author

Hata, S., primary, Miyazaki, H., additional, Miyazaki, S., additional, Mitsuhara, M., additional, Tanaka, M., additional, Kaneko, K., additional, Higashida, K., additional, Ikeda, K., additional, Nakashima, H., additional, Matsumura, S., additional, Barnard, J.S., additional, Sharp, J.H., additional, and Midgley, P.A., additional

Published
2011
Full Text
View/download PDF

41. Pharmacokinetics of a mixture of FVIIa and FX in rats

Author

Nakatomi, Y., primary, Matsui, H., additional, Tsuji, M., additional, Shiranita, A., additional, Nakamura, T., additional, Nakashima, T., additional, Gokudan, S., additional, Miyazaki, H., additional, Oonishi, S., additional, Kusumoto, E., additional, Tomokiyo, K., additional, Ogata, Y., additional, and Shigaki, T., additional

Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results